PNP23: COST-EFFECTIVENESS OF DRUG THERAPY FOR POSTHERPETIC NEURALGIA

Postherpetic neuralgia.

Postherpetic Neuralgia and Trigeminal Neuralgia

Postherpetic neuralgia (PHN) is an unpredictable complication of varicella zoster virus- (VZV-) induced herpes zoster (HZ) which often occurs in elderly and immunocompromised persons and which can induce psychosocial dysfunction and can negatively impact on quality of life. Preventive options for PHN include vaccination of high-risk persons against HZ, early use of antiviral agents, and robust ...

Treatment of postherpetic neuralgia.

Herpes zoster, a commonly seen condition in daily medical practice, is reported to occur in 10–20% of the population at some time during the lifespan. Chronic, intractable postherpetic neuralgia, a sequela of herpes zoster, presents a clinical challenge. In recent years, effective antiviral agents that can be used in the outpatient setting have been developed for the treatment of herpes zoster ...

Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

BACKGROUND A vaccine to prevent herpes zoster was recently approved by the United States Food and Drug Administration. We sought to determine the cost-effectiveness of this vaccine for different age groups. METHODS We constructed a cost-effectiveness model, based on the Shingles Prevention Study, to compare varicella zoster vaccination with usual care for healthy adults aged >60 years. Outcom...

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

This study assesses the cost-effectiveness of vaccination against herpes zoster (HZ) and postherpetic neuralgia in France, using a published Markov model. The cost-effectiveness of vaccinating individuals aged from 65 years or between 70 and 79 years was evaluated over their lifetime, from a third-party payer perspective. French-specific data were combined with results from clinical studies and...